Congenital Kaposiform Hemangioendothelioma with Kasabach–Merritt Phenomenon Successfully Treated with Low-Dose Radiation Therapy

Authors

  • Yogangi Malhotra M.D.,

    Corresponding author
    1. Division of Neonatology, Yale University, New Haven, Connecticut
    2. Division of Neonatology, Maria Fareri Children's Hospital, New York Medical College, Westchester, New York
    • Address correspondence to Yogangi Malhotra, M.D., Division of Neonatology, Asst. Professor, Pediatrics, Maria Fareri Children's Hospital at Westchester Medical Center, New York Medical College, Valhalla, NY 10595, or e-mail: yogimed@gmail.com.

    Search for more papers by this author
  • Catherine S. Yang M.D.,

    1. School of Medicine, Yale University, New Haven, Connecticut
    2. New York, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts
    Search for more papers by this author
  • Joseph McNamara M.D.,

    1. Department of Pediatrics, Yale University, New Haven, Connecticut
    Search for more papers by this author
  • Richard J. Antaya M.D.

    1. Department of Pediatrics, Yale University, New Haven, Connecticut
    2. Department of Dermatology, Yale University, New Haven, Connecticut
    Search for more papers by this author

Abstract

Kaposiform hemangioendothelioma (KHE) associated with Kasabach–Merritt phenomenon is a life-threatening vasculopathy. The current mainstay treatment for KHEs is corticosteroids and chemotherapy, but these medications do not work for all patients and carry significant side effects. We report a neonate with a large congenital KHE who responded extremely well to low-dose radiation therapy.

Ancillary